Key insights
- A social media post suggests Traws Pharma (TRAW) is poised for a rebound due to projected high revenue growth in antiviral and oncology therapeutics. Analysts forecast significant revenue increases, reaching $106.8 million in 2027 and $465 million by 2028, with an annual growth rate of 58.2%. While the post is bullish, its impact on the broader US equity market is minimal, primarily affecting TRAW's stock.
$TRAW. This is ready to fly.
They need the funding in the near term but have major revenue generating projects about to come to fruition.
Traws Pharma (TRAW) is experiencing significant, high-growth revenue projections, with analysts forecasting roughly $106.8 million in 2027 and accelerating to over $465 million by 2028. The company, which focuses on antiviral and oncology therapeutics, is projected to grow its revenue by an estimated 58.2% per year.
Key Revenue Projections & Financials
2027 Forecast: Average of $106.77 million, with estimates ranging from $0 to over $219 million.
2028 Forecast: Projected to reach $465.4 million.
Growth Outlook: Revenue is forecast to grow at 58.2% annually, significantly faster than the 10.6% US market average.
Recent Performance: As of Q2 2025, the company recognized $2.7 million in revenue, driven largely by deferred revenue from a licensed program, indicating the start of revenue acceleration.